Epinephrine nasal spray for anaphylaxis: a preferred needle-free self-treatment

Anaphylaxis is a rapid-onset, potentially fatal allergic reaction that requires immediate epinephrine administration. Traditional intramuscular auto-injectors can be hindered by needle phobia, incorrect use, limited availability, and injection-related injuries. Neffy, the first FDA-approved intranasal epinephrine spray, provides a needle-free, rapid, and user-friendly alternative. Its nasal formulation allows swift absorption, producing pharmacodynamic effects within one minute, comparable to conventional auto-injectors. By eliminating needles, Neffy reduces the risk of lacerations, ischemic complications, and accidental injuries, while enhancing adherence among patients or caregivers hesitant to use injections. Early data indicate effective management of anaphylaxis with this device, though further studies in broader populations are warranted. Adoption of nasal epinephrine may improve timely treatment, increase accessibility, and offer a safer, patient-centered approach to emergency allergic reactions.